<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056390</url>
  </required_header>
  <id_info>
    <org_study_id>SF124/2017</org_study_id>
    <nct_id>NCT04056390</nct_id>
  </id_info>
  <brief_title>Ablation STrategies for Repeat PrOcedures in Patients With Atrial Fibrillation Recurrences</brief_title>
  <acronym>ASTRO AF</acronym>
  <official_title>Ablation STrategies for Repeat PrOcedures in Patients With Atrial Fibrillation Recurrences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardioangiologisches Centrum Bethanien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CRO Kottmann</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardioangiologisches Centrum Bethanien</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate different ablation strategies in patients with AF&#xD;
      recurrences despite chronic PVI after prior catheter ablation.&#xD;
&#xD;
      The present study is a multi-centre prospective randomized study enrolling 256 patients with&#xD;
      drug-refractory AF despite previous AF ablation.&#xD;
&#xD;
      After PV remapping confirming durable PVI patients will be assigned to 2 different groups:&#xD;
      Group A: Substrate modification.&#xD;
&#xD;
      After obtaining a voltage map of the LA, substrate modification will be performed aiming at&#xD;
      low-voltage areas (LVA) &lt; 0.5mV.&#xD;
&#xD;
      Group B: LAA isolation. Patients will undergo LAA-isolation using the cryoballoon (CB).&#xD;
      Catheter ablation procedures will be performed with commercially available devices including&#xD;
      3D mapping systems (CARTO, EnSite) and irrigated radiofrequency current (RFC) ablation or&#xD;
      cryothermal balloon ablation (Arctic Front Advance).&#xD;
&#xD;
      The primary endpoint is freedom from documented recurrence of AF or any atrial&#xD;
      tachyarrhythmia lasting &gt; 30 seconds between day 91 and 365 after the index procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia Recurrence</measure>
    <time_frame>Day 91-365 after index ablation</time_frame>
    <description>Freedom from AF/AT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of periprocedural complications</measure>
    <time_frame>day 0 - day 365</time_frame>
    <description>Incidence of periprocedural complications such as cardiac perforation, thromboembolic events or bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of electrical cardioversions and hospitalizations</measure>
    <time_frame>day0 - day 365</time_frame>
    <description>Number of electrical cardioversions and hospitalizations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Substrate Modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After obtaining a voltage map of the LA, substrate modification by catheter ablation using an irrigated radio frequency current ablation catheter will be performed aiming at low-voltage areas (LVA) &lt; 0.5mV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAA Isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo LAA-isolation using the cryoballoon (CB). Six weeks later patients will undergo re-mapping. In case of residual conduction LAA-reisolation will be performed. In case of durable LAA isolation, interventional LAA occlusion is recommended.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy</intervention_name>
    <description>Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.</description>
    <arm_group_label>LAA Isolation</arm_group_label>
    <arm_group_label>Substrate Modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Symptomatic non-valvular atrial fibrillation despite prior ablation with an&#xD;
             indication for re-ablation according to current guidelines.&#xD;
&#xD;
               -  Permanent pulmonary vein isolation according to mapping with a spiral mapping&#xD;
                  catheter&#xD;
&#xD;
               -  Age 18-85 years.&#xD;
&#xD;
               -  Left atrial size &lt; 55mm.&#xD;
&#xD;
               -  Left ventricular ejection fraction ≥ 45%.&#xD;
&#xD;
               -  Patient is able to provide informed consent and is willing to comply with the&#xD;
                  study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for repeat ablation&#xD;
&#xD;
          -  Reconnected pulmonary veins according to mapping results with a spiral mapping&#xD;
             catheter&#xD;
&#xD;
          -  Minimal diameter of LAA neck ≥25mm&#xD;
&#xD;
          -  History of mitral valve surgery&#xD;
&#xD;
          -  Severe mitral valve regurgitation&#xD;
&#xD;
          -  Inability to be treated with oral anticoagulation&#xD;
&#xD;
          -  Presence of intracardiac thrombi&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease treated with long acting bronchodilatators&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Obstructive sleep apnea syndrome&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Participation in other clinical studies&#xD;
&#xD;
          -  Unwilling to follow the study protocol and to attend follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardioangiologisches Centrum Bethanien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boris Schmidt, MD</last_name>
    <phone>004969945028</phone>
    <phone_ext>0</phone_ext>
    <email>b.schmidt@ccb.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Sikorski</last_name>
    <phone>0049945028</phone>
    <phone_ext>0</phone_ext>
    <email>m.sikorski@ccb.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Schmidt, Dr.</last_name>
      <phone>+4969945028</phone>
      <phone_ext>110</phone_ext>
      <email>b.schmidt@ccb.de</email>
    </contact>
    <investigator>
      <last_name>Boris Schmidt, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolan R Tilz, MD</last_name>
      <phone>+49 451 500</phone>
      <phone_ext>44580</phone_ext>
      <email>Roland.Tilz@uksh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

